Metabolically-inactive glucagon-like peptide-1(9–36)amide confers selective protective actions against post-myocardial infarction remodelling

BACKGROUND: Glucagon-like peptide-1 (GLP-1) therapies are routinely used for glycaemic control in diabetes and their emerging cardiovascular actions have been a major recent research focus. In addition to GLP-1 receptor activation, the metabolically-inactive breakdown product, GLP-1(9–36)amide, also...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cardiovasc Diabetol
Egile Nagusiak: Robinson, Emma, Tate, Mitchel, Lockhart, Samuel, McPeake, Claire, O’Neill, Karla M., Edgar, Kevin S., Calderwood, Danielle, Green, Brian D., McDermott, Barbara J., Grieve, David J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4832495/
https://ncbi.nlm.nih.gov/pubmed/27079193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0386-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak